Capital Fund Management S.A. Decreases Stock Position in Bruker Corporation $BRKR

Capital Fund Management S.A. decreased its position in shares of Bruker Corporation (NASDAQ:BRKR) by 48.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,327 shares of the medical research company’s stock after selling 22,335 shares during the period. Capital Fund Management S.A.’s holdings in Bruker were worth $961,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grantham Mayo Van Otterloo & Co. LLC increased its position in shares of Bruker by 20.1% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 466,307 shares of the medical research company’s stock worth $19,212,000 after acquiring an additional 78,035 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in Bruker by 0.8% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 101,241 shares of the medical research company’s stock worth $4,171,000 after purchasing an additional 770 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Bruker in the 2nd quarter valued at approximately $87,000. Quadrant Capital Group LLC boosted its stake in shares of Bruker by 341.3% during the 2nd quarter. Quadrant Capital Group LLC now owns 14,400 shares of the medical research company’s stock valued at $593,000 after buying an additional 11,137 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB grew its position in shares of Bruker by 191.4% during the second quarter. Rhenman & Partners Asset Management AB now owns 123,315 shares of the medical research company’s stock worth $5,081,000 after buying an additional 81,000 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares in the company, valued at $581,016. The trade was a 16.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 27.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on BRKR shares. UBS Group increased their price objective on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Tuesday, November 4th. Barclays boosted their price objective on Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bruker in a report on Monday. Finally, Redburn Partners set a $60.00 price target on Bruker in a report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $50.25.

Bruker Stock Performance

Shares of BRKR stock opened at $48.03 on Friday. The company has a market cap of $7.30 billion, a P/E ratio of -300.19, a PEG ratio of 7.12 and a beta of 1.17. The business has a 50 day moving average of $40.48 and a two-hundred day moving average of $37.98. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.64. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period in the prior year, the firm earned $0.60 EPS. The business’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -125.00%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.